First Trust Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.51M | Buy |
1,880,290
+848,791
| +82% | +$4.29M | 0.01% | 1104 |
|
|
2025
Q1 | $5.46M | Buy |
+1,031,499
| New | +$5.46M | ﹤0.01% | 1272 |
|
|
2024
Q3 | – | Sell |
-94,854
| Closed | -$711K | – | 2467 |
|
|
2024
Q2 | $711K | Sell |
94,854
-282,871
| -75% | -$2.12M | ﹤0.01% | 2045 |
|
|
2024
Q1 | $3.77M | Buy |
377,725
+125,032
| +49% | +$1.25M | ﹤0.01% | 1441 |
|
|
2023
Q4 | $2.49M | Buy |
252,693
+18,271
| +8% | +$180K | ﹤0.01% | 1622 |
|
|
2023
Q3 | $1.79M | Buy |
234,422
+188,685
| +413% | +$1.44M | ﹤0.01% | 1727 |
|
|
2023
Q2 | $342K | Buy |
+45,737
| New | +$342K | ﹤0.01% | 2220 |
|
|
2023
Q1 | – | Sell |
-241,147
| Closed | -$1.86M | – | 2455 |
|
|
2022
Q4 | $1.86M | Buy |
241,147
+111,709
| +86% | +$861K | ﹤0.01% | 1725 |
|
|
2022
Q3 | $1.38M | Buy |
+129,438
| New | +$1.38M | ﹤0.01% | 1867 |
|